within Pharmacolibrary.Drugs.ATC.C;

model C07AA02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 1.8999999999999998e-05,
    adminDuration  = 600,
    adminMass      = 40 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0037,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C07AA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Oxprenolol is a non-selective beta-adrenergic receptor antagonist (beta-blocker) used primarily in the treatment of hypertension and angina pectoris. It was once widely prescribed for heart conditions, but its use is now limited or discontinued in many regions due to the development of newer beta-blockers with more favorable safety and efficacy profiles.</p><h4>Pharmacokinetics</h4><p>Single oral dose pharmacokinetics in healthy adult volunteers.</p><h4>References</h4><ol><li><p>Russo, ME, &amp; Covinsky, JO (1983). Oxprenolol hydrochloride: pharmacology, pharmacokinetics, adverse effects and clinical efficacy. <i>Pharmacotherapy</i> 3(2 Pt 1) 68–81. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6344036/\">https://pubmed.ncbi.nlm.nih.gov/6344036</a></p></li><li><p>Gregg, MR, et al., &amp; Kendall, MJ (1987). The pharmacokinetics of oxprenolol following oral and rectal dosing--a comparison of delivery systems and routes of administration. <i>Journal of clinical pharmacy and therapeutics</i> 12(2) 91–99. DOI:<a href=\"https://doi.org/10.1111/j.1365-2710.1987.tb00513.x\">10.1111/j.1365-2710.1987.tb00513.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3584272/\">https://pubmed.ncbi.nlm.nih.gov/3584272</a></p></li><li><p>Kendall, MJ, &amp; John, VA (1983). Oxprenolol: clinical pharmacology, pharmacokinetics, and pharmacodynamics. <i>The American journal of cardiology</i> 52(9) 27D–33D. DOI:<a href=\"https://doi.org/10.1016/0002-9149(83)90639-2\">10.1016/0002-9149(83)90639-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6356863/\">https://pubmed.ncbi.nlm.nih.gov/6356863</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C07AA02;
